| Chimeric antigen receptor T-cell therapy—assessment and management of toxicities SS Neelapu, S Tummala, P Kebriaei, W Wierda, C Gutierrez, FL Locke, ... Nature reviews Clinical oncology 15 (1), 47-62, 2018 | 2338 | 2018 |
| Ibrutinib and venetoclax for first-line treatment of CLL N Jain, M Keating, P Thompson, A Ferrajoli, J Burger, G Borthakur, ... New England Journal of Medicine 380 (22), 2095-2103, 2019 | 541 | 2019 |
| Clinical experience with the BCL 2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies CD DiNardo, CR Rausch, C Benton, T Kadia, N Jain, N Pemmaraju, ... American journal of hematology 93 (3), 401-407, 2018 | 457 | 2018 |
| Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults N Jain, KG Roberts, E Jabbour, K Patel, AK Eterovic, K Chen, ... Blood, The Journal of the American Society of Hematology 129 (5), 572-581, 2017 | 413 | 2017 |
| Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib P Jain, M Keating, W Wierda, Z Estrov, A Ferrajoli, N Jain, B George, ... Blood, The Journal of the American Society of Hematology 125 (13), 2062-2067, 2015 | 396 | 2015 |
| Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype N Jain, AV Lamb, S O’Brien, F Ravandi, M Konopleva, E Jabbour, Z Zuo, ... Blood, The Journal of the American Society of Hematology 127 (15), 1863-1869, 2016 | 365 | 2016 |
| Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies R Benjamin, C Graham, D Yallop, A Jozwik, OC Mirci-Danicar, G Lucchini, ... The Lancet 396 (10266), 1885-1894, 2020 | 330 | 2020 |
| Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study E Jabbour, H Kantarjian, F Ravandi, D Thomas, X Huang, S Faderl, ... The Lancet Oncology 16 (15), 1547-1555, 2015 | 315 | 2015 |
| Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab Y Abaza, H Kantarjian, G Garcia-Manero, E Estey, G Borthakur, E Jabbour, ... Blood, The Journal of the American Society of Hematology 129 (10), 1275-1283, 2017 | 302 | 2017 |
| Complex karyotype is a stronger predictor than del (17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based … PA Thompson, SM O'Brien, WG Wierda, A Ferrajoli, F Stingo, SC Smith, ... Cancer 121 (20), 3612-3621, 2015 | 299 | 2015 |
| Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis FPS Santos, HM Kantarjian, N Jain, T Manshouri, DA Thomas, ... Blood, The Journal of the American Society of Hematology 115 (6), 1131-1136, 2010 | 294 | 2010 |
| 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial CD DiNardo, A Maiti, CR Rausch, N Pemmaraju, K Naqvi, NG Daver, ... The Lancet Haematology 7 (10), e724-e736, 2020 | 290 | 2020 |
| Duvelisib, a novel oral dual inhibitor of PI3K-δ, γ, is clinically active in advanced hematologic malignancies IW Flinn, S O’Brien, B Kahl, M Patel, Y Oki, FF Foss, P Porcu, J Jones, ... Blood, The Journal of the American Society of Hematology 131 (8), 877-887, 2018 | 277 | 2018 |
| Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia CD DiNardo, CA Lachowiez, K Takahashi, S Loghavi, L Xiao, T Kadia, ... Journal of Clinical Oncology 39 (25), 2768-2778, 2021 | 266 | 2021 |
| Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia JA Burger, M Sivina, N Jain, E Kim, T Kadia, Z Estrov, ... Blood, The Journal of the American Society of Hematology 133 (10), 1011-1019, 2019 | 265 | 2019 |
| Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single … E Jabbour, NJ Short, F Ravandi, X Huang, N Daver, CD DiNardo, ... The Lancet Haematology 5 (12), e618-e627, 2018 | 260 | 2018 |
| Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase … H Kantarjian, F Ravandi, NJ Short, X Huang, N Jain, K Sasaki, N Daver, ... The Lancet Oncology 19 (2), 240-248, 2018 | 239 | 2018 |
| Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit'ALL' SS Neelapu, S Tummala, P Kebriaei, W Wierda, FL Locke, Y Lin, N Jain, ... Nature reviews Clinical oncology 15 (4), 218-218, 2018 | 227 | 2018 |
| Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States Q Chen, N Jain, T Ayer, WG Wierda, CR Flowers, SM O’Brien, MJ Keating, ... Journal of Clinical Oncology 35 (2), 166-174, 2017 | 201 | 2017 |
| Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: a propensity … K Sasaki, EJ Jabbour, F Ravandi, NJ Short, DA Thomas, ... Cancer 122 (23), 3650-3656, 2016 | 195 | 2016 |